Arvinas is a clinical-stage biopharmaceutical company focused on developing therapies that degrade disease-causing proteins using its proprietary PROTAC® Discovery Engine platform. The company has a robust preclinical pipeline and four investigational clinical-stage programs targeting breast cancer, prostate cancer, and neurodegenerative disorders.
